Clinical trials: Hepatitis; Epidemic
Hepatitis C, Chronic
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype…
- Trial name
- NCT01435226
- Testing
- GS-5885, GS-9451, tegobuvir
- Where
- 51 sites in United States, Germany
- Volunteers
- 170 people
- Sponsor
- Gilead Sciences
Liver Fibrosis, HEPATITIS B CHRONIC
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
The purpose of this study is to determine whether an investigational drug DCB-BO1202 is effective and safe in the treatment of liver fibrosis in HBV patients having experienced intermediate stage hepatocellular carcinoma (HCC)
- Conditions
- Liver Fibrosis, HEPATITIS B CHRONIC, Hepatocellular Carcinoma
- Trial name
- NCT02289300
- Testing
- DCB-BO1202
- Where
- Taiwan
- Sponsor
- A2 Healthcare Taiwan Corporation
Adolescent Health Services, Immunization
Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina
The North Carolina Immunization Branch will evaluate the use of the CDC program to improve adolescent vaccination practices (called Assessment, Feedback, Incentives, and eXchanges, or AFIX).
- Trial name
- AFIX (NCT01544764)
- Testing
- Assessment , Feedback, Incentives, and eXchange Program
- Where
- 2 sites in United States
- Volunteers
- 91 people
- Sponsor
- University of North Carolina, Chapel Hill
Liver Injury, Hepatitis B Virus Infection History
Liver Injury by Statins in Patients With History of Hepatitis B Virus Infection
The purpose of this study is to investigate the incidence of liver injury by statins in coronary heart disease (CHD) patients with history of hepatitis B virus (HBV) infection.
- Trial name
- LISHBV (NCT02808299)
- Testing
- HBV infection history
- Where
- China
- Volunteers
- 600 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatitis C, HIV
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
The investigators believe that boceprevir's drug concentrations will be reduced when administered in combination with etravirine.
- Trial name
- NCT01427504
- Testing
- boceprevir; etravirine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hepatitis C
Plasma MicroRNA for Prediction of Hepatocellular Carcinoma
100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78).
- Trial name
- NCT05449847
- Testing
- Blood Sampling
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Benha University
Hepatocellular Carcinoma
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
The purpose of this study is to investigate the efficacy and safety of Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses.
- Trial name
- NCT05897138
- Testing
- Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Hepatitis C, Chronic
Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)
Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695)
- Trial name
- NCT01081158
- Testing
- Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron), Drug: SCH 900518 Biologic: Peginterferon alfa-2b, Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Infection With HIV Co-Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02457611
- Testing
- LDV/SOF
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
- Trial name
- AGL13 (NCT06843148)
- Testing
- Niacin (250mg)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Université de Sherbrooke
Chronic Hepatitis B
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
The study is aimed to explore the safety and efficacy of the pulse usage , comparing to continuous usage, of Peginterferon alfa-2b Injection (PEG IFN α-2b) Combined With tenofovir alafenamide (TAF) in treatment of naive chronic…
- Trial name
- NCT05490836
- Testing
- PEG IFN α-2b; TAF
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Huashan Hospital
Hepatitis C
Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C
The purpose of this open-label study is to assess the safety, antiviral activity, and pharmacokinetics of 9 subcutaneous injections of miravirsen monotherapy (5 weekly doses over 5 weeks, followed by a further 4 doses once every…
- Trial name
- NCT01727934
- Testing
- Miravirsen sodium
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Santaris Pharma A/S
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic parameters of SOF/VEL administered…
- Trial name
- NCT04382404
- Testing
- Sofosbuvir-Velpatasvir Drug Combination
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Catherine Anne Chappell
Hepatitis C, Chronic
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis C treated with Pegasys and Copegus.
- Trial name
- NCT01200225
- Where
- France
- Volunteers
- 1,155 people
- Sponsor
- Hoffmann-La Roche
HIV Infection, HIV Infections
Integration of Family Planning and HIV Services in Tanzania
HIV positive women and couples have broad reproductive health needs that are not always met within HIV services. The integration of family planning (FP) services into Tanzania's HIV Care and Treatment Clinics (CTC) will address…
- Trial name
- NCT00941876
- Testing
- Facilitated Referral
- Where
- Tanzania
- Volunteers
- 864 people
- Sponsor
- FHI 360
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO), work productivity and safety data of the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), ±…
- Trial name
- VERITAS (NCT02636608)
- Volunteers
- 244 people
- Sponsor
- AbbVie
Chronic Hepatitis b
Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines
Treatment with Tenofovir Alafenamide(TAF) in Chronic Hepatitis B (CHB) patients classified as beyond treatment indication of current international guidelines (e.g.
- Trial name
- ATTENTION (NCT03753074)
- Testing
- Tenofovir Alafenamide
- Where
- 10 sites in South Korea
- Volunteers
- 780 people
- Sponsor
- Young-Suk Lim
Hepatitis C
Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir
To evaluate the early detection of HCC in patients Taking Sofosbuvir and Daclatasvir.
- Trial name
- NCT03247296
- Testing
- Sofosbuvir 400 mg, Daclatasvir, Ribavirin
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- MTI University
Cirrhosis Portal
EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.
The aim of the current study is to assess if EUS-PPGM could predict the treatment response and outcomes of varices to endoscopic variceal ligation (EVL) in patients with chronic hepatitis.
- Trial name
- NCT05597488
- Testing
- EUS guided portal pressure gradient measurement
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese University of Hong Kong
Chronic Hepatitis C
Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.
- Trial name
- NCT00823862
- Testing
- SD-101, ribavirin
- Where
- 5 sites in Poland
- Volunteers
- 34 people
- Sponsor
- Dynavax Technologies Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.